nicotinamide mononucleotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
Trace amounts of NMN have been reported in certain plant foods, including edamame, avocado, broccoli, cucumber, and cabbage. Reported concentrations vary widely because analytical methods differ and food matrices complicate extraction. Endogenous production in cells is generally considered more quantitatively important than dietary intake, though precise human turnover rates are difficult to establish. Commercial NMN for research or consumer products is commonly made through enzymatic synthesis or chemical phosphorylation routes. Regulatory classification differs by country; in some jurisdictions NMN is sold as a supplement, while in others it is treated as a novel food ingredient or restricted substance.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure combines a nicotinamide ring, a ribose sugar, and a phosphate group. As an intermediate in the NAD+ salvage pathway, NMN is converted to nicotinamide adenine dinucleotide, a coenzyme central to cellular redox reactions. NAD+ also serves as a substrate for enzymes involved in DNA repair, stress responses, and metabolic regulation. The compound is therefore part of normal cellular biochemistry rather than an exclusively synthetic molecule.
NMN occurs in many living systems, including bacteria, yeast, plants, and mammals. Dietary sources are present in foods such as edamame, avocado, broccoli, and various meats, but amounts vary widely and are generally lower than those used in research settings. Laboratory production often relies on enzymatic synthesis or chemical phosphorylation of nicotinamide riboside, and commercial material is typically supplied as a white to off-white powder. Because NMN is hygroscopic and sensitive to heat, moisture, and pH extremes, its handling requires care to preserve identity and purity. Aqueous preparation should be done with attention to pH and temperature to limit hydrolysis.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in cells. Its structure consists of a nicotinamide ring linked to ribose phosphate, and the compound serves as an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+. In this pathway, nicotinamide phosphoribosyltransferase converts nicotinamide and phosphoribosyl pyrophosphate into NMN, after which NMN adenylyltransferase attaches an adenylate group to produce NAD+. Because NAD+ participates in redox reactions and signaling, NMN occupies a central position in cellular metabolism. The molecule is distinct from nicotinamide riboside, though the two are related in NAD+ precursor research.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
The Journal of Pharmacy Practice is a bimonthly peer-reviewed healthcare journal that covers the field of pharmacy, including new drugs and therapies, pharmacokinetics, drug administration, and adverse drug reactions. The editor-in-chief is Michael Liu (Touro College of Pharmacy). It was established in 1988 and is currently published by SAGE Publications.
There are many applications for AMS throughout a variety of disciplines. AMS is most often employed to determine the concentration of 14C, e.g. by archaeologists for radiocarbon dating. Compared to other radiocarbon dating methods, AMS requires smaller sample sizes (about 50 mg), while yielding extensive chronologies. MS technology has expanded the scope of radiocarbon dating. Samples ranging from 50,000 years old to 100 years old can be successfully dated using AMS, as other forms of mass spectrometry provide insufficient suppression of molecular isobars to resolve 13CH and 12CH2 from 14C atoms. Because of the long half-life of 14C, decay counting requires significantly larger samples. 10Be, 26Al, and 36Cl are used for surface exposure dating in geology. 3H, 14C, 36Cl, and 129I are used as hydrological tracers. Accelerator mass spectrometry is widely used in biomedical research. In particular, 41Ca has been used to measure bone resorption in postmenopausal women. List of accelerator mass spectrometry facilities Arizona Accelerator Mass Spectrometry Laboratory
Moroder studied chemistry at the University of Padova, where he graduated 1965 in chemistry with the doctoral thesis on synthesis of S-peptide of ribonuclease A in the laboratory of Ernesto Scoffone at the Institute of Organic Chemistry. In 1968 he joined Klaus H. Hofmann's Group at the University of Pittsburgh to work on chemical synthesis of the peptidic adrenocorticotropic hormone and its derivatives. Moroder habilitated in 1971 at the University of Padova in Chemistry of Natural Products. 1975 he became a senior research fellow in the Department of Peptide Chemistry at the Max Planck Institute for Biochemistry (MPIB) in Martinsried headed by Erich Wünsch. Between 1991 and 2008 he was the head of the Laboratory of Bioorganic chemistry at the MPIB. Since 1994 he was an adjunct professor at the Technical University of Munich.
(E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP or HMB-PP) is an intermediate of the MEP pathway (non-mevalonate pathway) of isoprenoid biosynthesis. The enzyme HMB-PP synthase (GcpE, IspG) catalyzes the conversion of 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MEcPP) into HMB-PP. HMB-PP is then converted further to isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) by HMB-PP reductase (LytB, IspH). HMB-PP is an intermediate in the non-mevalonate pathway for the biosynthesis of the isoprenoid precursors isopentenyl pyrophosphate and dimethylallyl pyrophosphate. Most gram-negative bacteria, the photosynthetic cyanobacteria and green algae use only this pathway, while higher plants also use the mevalonate pathway. The enzyme 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase uses two reduced ferredoxin proteins per molecule of the precursor MEcPP to convert it to HMB-PP:
Sources: en.wikipedia.org
== Distribution and habitat == Panaeolus cyanescens is a coprophilous (dung-inhabiting) species which occurs in both the Neotropics and Paleotropics. It has been found in Vietnam, Africa (including South Africa, Mauritius, Madagascar and Democratic Republic of the Congo), Australia, Belize, the Caribbean (Bermuda, Grenada, Barbados Jamaica, Trinidad, and Puerto Rico), Costa Rica, India, Malaysia, Indonesia, Sri Lanka, Cambodia, Thailand, Japan, Mexico, Oceania (Fiji and Samoa), the Philippines, South America (Bolivia, Brazil, Paraguay, Colombia, Venezuela, and Ecuador), South Korea, and the United States (California, Hawaii, Louisiana, Mississippi, Alabama, Florida, Tennessee, Texas, Kentucky, Virginia, Georgia, and North Carolina).
When the Union of South Africa was established in 1910, the Parliament was bicameral and consisted of the King or the Queen, the Senate, and the House of Assembly (known in Afrikaans as the Volksraad).
Chronic cholestasis is a feature in primary sclerosing cholangitis (PSC). PSC is a rare and progressive cholestatic liver disease characterized by narrowing, fibrosis, and inflammation of intrahepatic or extrahepatic bile ducts, leading to reduced bile flow or formation (i.e., cholestasis). The pathogenesis of PSC remains unclear but probably involves a combination of environmental factors and genetic predisposition. Notably, 70-80% of patients with PSC are comorbid with inflammatory bowel disease (e.g., ulcerative colitis or Crohn's colitis), suggesting there exists a link between the two. PSC predominantly affects males (60–70%) of 30–40 years of age. The disease has an incidence is 0.4–2.0 cases/100,000 and a prevalence of 16.2 cases/100,000, making it a rare disease. Nonetheless, PSC accounts for 6% of liver transplants in the US due to its eventual progression to end-stage liver disease, with a mean transplant-free survival of 21.3 year. Though 40-50% of patients are asymptomatic, commonly reported symptoms include abdominal pain in the right upper quadrant, pruritus, jaundice, fatigue, and fever. The most common signs are hepatomegaly and splenomegaly. Prolonged cholestasis in PSC may cause fat-soluble vitamin deficiency leading to osteoporosis Diagnosis requires elevated serum alkaline phosphatase persisting for at least 6 months and the presence of bile duct strictures on cholangiogram. Unlike primary biliary cholangitis, PSC lacks a diagnostic autoantibody or reliable biomarker of disease progression.
This term acquired a pejorative connotation in 18th-century Russia, and it currently means "petty bourgeois" or "narrow-minded philistine". The entire city of the late 17th century is contained within contemporary Moscow's Central Administrative Okrug. Numerous disasters befell the city during this period. Plague epidemics ravaged Moscow in 1570–1571, 1592, and 1654–1656. The plague killed more than 80% of the population in 1654–1655. Fires burned down much of the wooden city in 1626 and 1648. In 1712, Peter the Great moved his government to the newly built city of Saint Petersburg on the coast of the Baltic Sea.
=== Measurement and invalidation of ORAC === Measurement of polyphenol and carotenoid content in food is not a straightforward process, as antioxidants collectively are a diverse group of compounds with different reactivities to various ROS. In food science analyses in vitro, the oxygen radical absorbance capacity (ORAC) was once an industry standard for estimating antioxidant strength of whole foods, juices and food additives, mainly from the presence of polyphenols. Earlier measurements and ratings by the United States Department of Agriculture were withdrawn in 2012 as biologically irrelevant to human health, referring to an absence of physiological evidence for polyphenols having antioxidant properties in vivo. Consequently, the ORAC method, derived only from in vitro experiments, is no longer considered relevant to human diets or biology, as of 2010. Alternative in vitro measurements of antioxidant content in foods – also based on the presence of polyphenols – include the Folin-Ciocalteu reagent, and the Trolox equivalent antioxidant capacity assay.
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.